ABSTRACT
Scope To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals.
Methods and results In 358 random volunteers from the PREDIMED trial (Prevención con Dieta Mediterránea), we assessed the 1-year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; N=120) or nuts (MedDiet-Nuts; N=119) versus a low-fat control diet (N=119). In a secondary, observational approach, we studied whether volunteers with large increments in MedDiet adherence (>2 score points) were associated with 1-year improvements in biomarkers (relative to those worsening their adherence). The MedDiet-VOO intervention increased platelet activating factor-acetylhydrolase activity in high-density lipoproteins (HDLs) by 7.5% [95% confidence interval: 0.17; 14.8] and decreased HDL-bound α1-antitrypsin levels by 6.1% [−11.8; −0.29]. The MedDiet-Nuts one reduced non-esterified fatty acid concentrations by 9.3% [−18.1; −0.53]. Only the low-fat diet was associated with increases in platelet factor-4 and prothrombin factor1+2 levels versus baseline (P=0.012 and P=0.003, respectively, according to Wilcoxon signed-rank tests). Finally, large MedDiet increments were associated with less fibrinogen (−9.5% [−18.3; −0.60]) and non-esterified fatty acid concentrations (−16.7% [−31.7; −1.74]).
Conclusion Following a MedDiet improves atherothrombosis biomarkers in high cardiovascular risk individuals.
Competing Interest Statement
X.P. reports to be a board member, lecture fees, and grants from Ferrer International; to be a board member and grants from the Residual Risk Reduction Initiative Foundation; personal fees from Abbott Laboratories; lecture fees and grants from Merck and Roche; lecture fees from Danone, Esteve, Menarini, Mylan, LACER, and Rubio Laboratories; and grants from Sanofi, Kowa, Unilever, Boehringer Ingelheim, and Karo Bio. J.S.-S. reports to be a board member and personal fees from Instituto Danone Spain; to be a board member and grants from the International Nut and Dried Fruit Foundation; personal fees from Aguas Font Vella Lanjarón, and Danone S.A; and grants from Eroski Distributors. F.A. reports personal fees from Menarini and AstraZeneca. L.S.-M. reports to be a board member of the Mediterranean Diet Foundation and the Beer and Health Foundation. E.R. reports personal fees, grants, and nonfinancial support from the California Walnut Commission, Merck Sharp & Dohme, Alexion, and Ferrer International; personal fees and nonfinancial support from Aegerion, Amarin, and Danone; personal fees and grants from Sanofi; and grants from Amgen and Pfizer. R.E. reports to be a board member of the Research Foundation on Wine and Nutrition, the Beer and Health Foundation, and the European Foundation for Alcohol Research; personal fees from KAO Corporation; lecture fees from Instituto Cerventes, Fundacion Dieta Mediterranea, Cerveceros de España, Lilly Laboratories, AstraZeneca, and Sanofi; and grants from Novartis, Amgen, Bicentury, and Grand Fountaine. The rest of the authors have nothing to disclose.
Clinical Trial
ISRCTN35739639
Funding Statement
This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, and CD17/00122 (A.H.)], and Agència de Gestió d’Ajuts Universitaris i de Recerca (2017 SGR 222). CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Considering that we do not have the explicit written consent of the study volunteers to yield their deidentified data at the conclusion of the study, individual participant data cannot be shared. The study protocol is available in the main publication of the study1 and in the study website (http://www.predimed.es/uploads/8/0/5/1/8051451/_1estr_protocol_olf.pdf), and a summary of the dietary intervention is also available in Supplemental Methods.
Abbreviations
- MedDiet
- Traditional Mediterranean Diet
- MedDiet-Nuts
- Traditional Mediterranean Diet enriched in nuts
- MedDiet-VOO
- Traditional Mediterranean Diet enriched in virgin olive oil
- NEFA
- non-esterified fatty acids
- PAF-AH
- platelet activating factor-acetylhydrolase
- PAI-1
- plasminogen activator inhibitor-1